A Missouri state court has granted final approval to a massive $7.25 billion settlement resolving extensive litigation over claims that the popular weedkiller Roundup causes cancer. Judge Timothy Boyer formally approved the nationwide class-action agreement on Friday, declaring the terms to be "fair, reasonable, and adequate."

The multibillion-dollar accord is designed to conclusively address years of costly legal battles faced by the German biotech and pharmaceutical giant Bayer. The resolution covers both current Roundup users already suffering from non-Hodgkin lymphoma and individuals who may contract the illness in the future.

Terms and Payout Structure of the Agreement

Under the approved nationwide settlement, participating Roundup users diagnosed with non-Hodgkin lymphoma will receive payouts ranging from $10,000 to $165,000. Individual compensation amounts are determined by specific criteria:

  • How frequently the individual used the weedkiller product
  • When they received their non-Hodgkin lymphoma diagnosis
  • The severity of their illness

Background of the Roundup Controversy

Roundup was originally developed by Monsanto during the 1970s. The core controversy centers around glyphosate, the weedkiller's active ingredient. In 2015, the International Agency for Research on Cancer—a division of the World Health Organization—classified glyphosate as a probable human carcinogen.

While Bayer and regulatory bodies like the US Environmental Protection Agency have disputed those specific findings, the classification triggered a wave of litigation. Over the years, juries in multiple US states awarded billions of dollars to users who claimed the herbicide caused their cancer, forcing Bayer into prolonged legal battles.

Legal Outlook and Resolution

Friday's judicial approval marks a decisive milestone in Bayer's strategy to mitigate ongoing risks and effectively end tens of thousands of pending lawsuits. The class-action settlement arrives on the heels of a favorable US Supreme Court ruling over the summer, which barred Bayer from being sued in state courts over product warning labels.

Combined with the Supreme Court decision and past individual settlements, the $7.25 billion agreement is expected to largely put the decade-long legal crisis behind the company.